Differential susceptibility to tetracycline,oxytetracycline and doxycycline of the calf pathogens Mannheimia haemolytica and Pasteurella multocida in three growth media

For clinical isolates of bovine Mannheimia haemolytica and Pasteurella multocida, this study reports minimum inhibitory concentration (MIC) differences for tetracycline, oxytetracycline and doxycycline between cation‐adjusted Mueller‐Hinton broth (CAMHB), foetal bovine serum (FBS) and Roswell Park Memorial Institute (RPMI) medium. MICs were determined according to CLSI standards and additionally using five overlapping sets of twofold dilutions. Matrix effect: (a) free drug MICs and minimum bactericidal concentrations (MBC) for all drugs were significantly higher in FBS than in CAMHB for both pathogens (p < 0.001); (b) MICs and MBCs were higher for CAMHB and FBS compared to RPMI for P. multocida only. Net growth rate for P. multocida in CAMHB was significantly slower than in FBS and higher than in RPMI, correlating to MIC and MBC ranking. Drug effect: doxycycline MICs and MBCs were significantly lower (p < 0.001) in both CAMHB and FBS than tetracycline and oxytetracycline for both pathogens. Only for M. haemolytica were oxytetracycline MIC and MBC significantly lower than tetracycline, precluding the use of tetracycline to predict oxytetracycline susceptibility in this species. Determining potencies of tetracyclines in a physiological medium, such as FBS, is proposed, when the objective is correlation with pharmacokinetic data for dosage determination.     

Clinical Chemical Studies in Aleutian Disease of Mink

Clinical chemical determinations were carried out on blood removed by cardiac puncture from 49 mink affected with Aleutian disease and 25 normal animals and the respective differences tested for statistical significance. Blood urea nitrogen, serum total protein and globulin, thymol turbidity, glutamic oxalacetic and glutamic pyruvic transaminases and amylase were definitely elevated in the affected animals whereas serum calcium, albumin and A/G ratio were depressed. No statistically significant difference was apparent between the two groups in the comparison of inorganic phosphorus, alkaline and acid phosphatases, bilirubin, total cholesterol and esters, cephalin-cholesterol flocculation (3+ in each case), sodium, potassium, chloride, CO₂-combining power, leucine aminopeptidase and lactic dehydrogenase (means: over 2,000 u./ml.). For both the control and affected mink, the distribution of serum lactic dehydrogenase isozymes resembled that of human homologous serum hepatitis. Electrophoresis of serum proteins confirmed earlier findings of hypergammaglobulinemia in the diseased animals but a fast-moving or pre-albumin component, averaging 4% of the total protein, occurred in both the diseased and normal mink.     

Inflammation: a clinical perspective. The Ciba-Geigy Prize for Research in Animal Health

The cardinal signs of acute inflammation have been recognised for almost 2000 years, but it is only in the last hundred years that significant progress has been made in understanding the underlying cellular response. Our knowledge of the chemical messengers which regulate and in some cases lead to persistence of the inflammatory process is, as yet, incomplete, but it is hoped that further research at this level will lead to the development of more effective therapeutic agents.     

Pharmacology and therapeutics of non-steroidal anti-inflammatory drugs in the dog and cat: 2 Individual agents

The general pharmacology of the non-steroidal anti-inflammatory drugs (NSAIDs) used in dogs and cats has been described in part 1 of this review (Lees and others 1991). This paper outlines the properties of the individual agents as they are used in small animal practice. The NSAIDs which have been used extensively in small animals include the older agents such as Aspirin, cinchophen and phenylbutazone. These agents have previously been used empirically by extrapolation of dosages from other species and by clinical experience. Studies are now available which provide a scientific rationale for the dosage rate recommended. A number of new drugs have recently been licensed for use in the dog or may be licensed in the near future. These include flunixin, carprofen and tolfenamic acid and the data generated from these products provides very useful information for formulating I effective dosage regimens. There are also some NSAIDs such as piroxicam which have been investigated in the dog because they have particular properties which may be of use in common clinical conditions and others, such as Paracetamol and Ibuprofen, which are readily available to the public and which owners may administer to dogs or cats at toxic doses.